RxDoctor Payments DataLook up a doctor →

Arindam Banerjee, MD

Interventional Cardiology · Conroe, TXNPI 1861402810

Payments from drug & device makers

$357,457in general payments, 2019–2025

Across 1,750 payments — averaging $204.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$102K
  • Lilly USA, LLC$85K
  • Esperion Therapeutics, Inc.$79K
  • Medtronic$32K
  • Johnson & Johnson$20K
  • Abbott$12K
  • plus $28K from 53 others

What the payments were for

  • Consulting fees$8,1332%
  • Speaking & faculty fees$272,39076%
  • Travel & lodging$14,0564%
  • Food & beverage$62,85518%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim105$102,192
Lilly USA, LLC95$84,520
Esperion Therapeutics, Inc.139$79,270
Medtronic(2 entities)411$31,746
Johnson & Johnson59$19,514
Abbott210$12,218
Sanofi-aventis U.S. LLC25$3,940
Cardiovascular Systems Inc.55$3,206
Boston Scientific50$2,978
Amgen188$2,755
Avinger Inc.34$2,041
Biotronik Inc.27$1,822
Novartis98$1,539
Angiodynamics, Inc.18$862
Endologix LLC3$717
Merck26$610
Bard Peripheral Vascular, Inc.20$572
BD4$545
E.r. Squibb & Sons, L.L.C.34$516
Biosense Webster, Inc.5$514
W. L. Gore & Associates, Inc.4$513
Impulse Dynamics (USA) Inc.8$415
Edwards Lifesciences4$362
AstraZeneca21$337
Inari Medical, Inc.3$291
Polarityte, Inc.2$288
Abiomed2$283
Philips North America LLC4$251
Regeneron Healthcare Solutions, Inc.3$233
Pfizer12$202
Actelion Pharmaceuticals US, Inc.7$192
Penumbra, Inc.2$192
Surmodics, Inc.1$186
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)9$151
Siemens Medical Solutions USA, Inc.3$138
Bayer7$137
Imperative Care, Inc1$126
Paratek Pharmaceuticals, Inc.1$125
Cook Medical LLC2$111
Shockwave Medical, Inc3$110
Heartflow, Inc.6$104
Scpharmaceuticals Inc.6$101
Tactile Systems Technology Inc6$87
Chiesi USA, Inc.4$73
Lexicon Pharmaceuticals, Inc.2$52
Janssen Scientific Affairs, LLC1$35
GRT US Holding, Inc.2$34
Nevro Corp.1$33
Bolton Medical Inc1$29
Arbor Pharmaceuticals, Inc.2$27
Bardy Diagnostics, Inc.2$22
United Therapeutics Corporation5$22
Astellas Pharma US Inc1$21
Cardiva Medical, Inc.1$20
Cardinal Health 200 LLC1$18
Kestra Medical Technology Services, Inc.1$17
Cashflow Solutions, LLC1$16
Kowa Pharmaceuticals America, Inc.1$15
Cvrx, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$357,457 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$2,063,511
Medicare patients
872
Services billed
13,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban434$485,864
XareltoRivaroxaban177$181,808
AdempasRiociguat12$149,571
EntrestoSacubitril/Valsartan89$118,073
Ambrisentan18$107,956
BrilintaTicagrelor133$90,817
Repatha SureclickEvolocumab61$50,960
NexlizetBempedoic Acid/Ezetimibe26$20,717
Repatha PushtronexEvolocumab26$16,512
Repatha SyringeEvolocumab17$9,778
Ranolazine ErRanolazine64$7,594
ClopidogrelClopidogrel Bisulfate624$7,279
Amiodarone Hcl65$4,297
Metoprolol Succinate287$4,161
Atorvastatin Calcium342$3,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$485,864434 claims
Johnson & JohnsonXarelto$19,514$181,808177 claims
BayerAdempas$137$149,57112 claims
NovartisEntresto$1,539$118,07389 claims
AstraZenecaBrilinta$337$90,817133 claims
Esperion Therapeutics, Inc.Nexlizet$79,270$20,71726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →